CVRx (CVRX) to Release Quarterly Earnings on Monday

CVRx (NASDAQ:CVRXGet Rating) is set to issue its quarterly earnings data after the market closes on Monday, April 25th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter. CVRx has set its Q1 2022 guidance at EPS and its FY 2022 guidance at EPS.Parties interested in registering for the company’s conference call can do so using this link.

CVRx (NASDAQ:CVRXGet Rating) last issued its quarterly earnings data on Tuesday, February 15th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.09). The firm had revenue of $3.66 million during the quarter, compared to analyst estimates of $3.96 million. On average, analysts expect CVRx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of CVRx stock opened at $4.86 on Monday. CVRx has a twelve month low of $4.81 and a twelve month high of $29.00. The company has a 50-day simple moving average of $6.91.

Several equities analysts recently weighed in on CVRX shares. Canaccord Genuity Group cut their price target on CVRx from $30.00 to $17.00 in a research note on Thursday, January 13th. Canaccord Genuity Group cut their price target on CVRx from $30.00 to $17.00 in a research note on Thursday, January 13th. Finally, Zacks Investment Research upgraded CVRx from a “sell” rating to a “hold” rating in a research note on Tuesday, January 11th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, CVRx currently has a consensus rating of “Buy” and a consensus price target of $22.37.

In other news, Director Kirk G. Nielsen acquired 40,008 shares of the business’s stock in a transaction on Tuesday, February 22nd. The stock was bought at an average cost of $7.94 per share, for a total transaction of $317,663.52. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kirk G. Nielsen acquired 26,659 shares of the business’s stock in a transaction on Friday, February 18th. The shares were purchased at an average price of $7.92 per share, with a total value of $211,139.28. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 70,067 shares of company stock valued at $556,819.

Several hedge funds have recently bought and sold shares of CVRX. Morgan Stanley purchased a new stake in shares of CVRx in the third quarter valued at approximately $169,000. Royal Bank of Canada purchased a new stake in shares of CVRx in the third quarter valued at approximately $71,000. California State Teachers Retirement System purchased a new stake in shares of CVRx in the third quarter valued at approximately $73,000. UBS Group AG grew its position in shares of CVRx by 901.2% in the third quarter. UBS Group AG now owns 8,600 shares of the company’s stock valued at $142,000 after purchasing an additional 7,741 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of CVRx in the third quarter valued at approximately $229,000. Institutional investors and hedge funds own 72.60% of the company’s stock.

About CVRx (Get Rating)

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF.

Featured Articles

Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.